More Potent and Metabolically Stable HIV/AIDS Therapeutics
Researchers at Purdue University have developed a series of alkenyldiarylmethane (ADAM) NNRTIs that inhibit the cytopathic effect of HIV-1 in CEM-SS cells and MT-4 cells and offer potential value in the treatment of AIDS. These ADAMs were developed through research on an original 25 ADAMs tested with different methyl ester bioisosteres at three different locations. This research resulted in inhibitors proven to be more potent and designed to be more metabolically stable than the original lead compound. This new series of compounds also includes an inhibitor effective against the resistant K103N mutant reverse transcriptase.
More potent inhibitor Metabolically stable K103N mutant inhibitor
AIDS/HIV treatment Research & Development
Mark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology
United States
None
美国
